Eicosapentaenoic acid and arachidonic acid: collaboration and not antagonism is the key to biological understanding

Prostaglandins Leukot Essent Fatty Acids. 2002 Jan;66(1):83-90. doi: 10.1054/plef.2001.0338.

Abstract

Much of the literature on omega-3 and omega-6 fatty acids suggests that desirable effects of omega-3 fatty acids are in part related to depletion of arachidonic acid (AA). However, in rats and humans, we have found that low doses of EPA actually elevate membrane AA phospholipid concentrations. In patients with schizophrenia, treatment with eicosapentaenoic acid (EPA) produced clinical improvement, but that improvement was greater at a dose of 2 g/day than at 4 g/day. The improvement was not significantly correlated with changes in either EPA or docosahexaenoic acid (DHA) but was highly significantly positively correlated with rises in red cell membrane AA. We suggest that elevation of concentrations of both AA and EPA in cell membranes may be important for health.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Animals
  • Arachidonic Acid / analysis*
  • Arachidonic Acid / blood
  • Dietary Fats / administration & dosage
  • Dietary Fats / analysis
  • Dietary Fats / pharmacology*
  • Dietary Fats / therapeutic use
  • Dose-Response Relationship, Drug
  • Eicosapentaenoic Acid / administration & dosage*
  • Eicosapentaenoic Acid / analysis
  • Eicosapentaenoic Acid / pharmacology*
  • Eicosapentaenoic Acid / therapeutic use
  • Erythrocyte Membrane / drug effects*
  • Erythrocyte Membrane / metabolism
  • Fatty Acids, Omega-6
  • Fatty Acids, Unsaturated / pharmacology
  • Female
  • Humans
  • Rats
  • Rats, Wistar
  • Schizophrenia / blood
  • Schizophrenia / drug therapy
  • Schizophrenia / metabolism

Substances

  • Dietary Fats
  • Fatty Acids, Omega-6
  • Fatty Acids, Unsaturated
  • Arachidonic Acid
  • Eicosapentaenoic Acid